Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Withdrawn before enrolling · Phase 2

Conditions studied: Resectable, Non-functioning Pituitary Adenoma

In brief

The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

Key facts

Study ID

NCT01203618

Run by

Morphotek

People needed

0

Starts

2011-02-01

Expected to finish

2013-08-01

Last updated by the study team

2013-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females >18 years old
• Diagnosis of non-functional pituitary adenoma
• Able and willing to undergo surgical resection of the pituitary tumor
• Significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form

You may not qualify if…

• Presence of clinically significant pituitary apoplexy
• Presence of hormone-secreting adenomas
• Presence of compressive optic neuropathy due to pituitary tumor
• No prior surgical, medical, or radiation therapy in the last 6 months

Where it is running

• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.